PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
11.91%
Growth of 11.91% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-92.37%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -2.94%. Seth Klarman would investigate competitive advantage potential.
229.93%
Growth of 229.93% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-32.16%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.51%. Seth Klarman would investigate competitive position.
25.44%
R&D growth while Drug Manufacturers - Specialty & Generic reduces spending. Peter Lynch would examine strategic differences.
2.92%
G&A change of 2.92% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
16.45%
Marketing expense change of 16.45% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-79.47%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
7.89%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
48.89%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
32.50%
Interest expense change of 32.50% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
23.54%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.87%. Jim Chanos would check for overinvestment.
1096.55%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.58%. Joel Greenblatt would investigate advantages.
-176.85%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-19.65%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 1.73%. Seth Klarman would investigate causes.
-6.91%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
1508.25%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.95%. Jim Chanos would check for issues.
450.39%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.12%. Joel Greenblatt would investigate advantages.
413.09%
Margin change of 413.09% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
317.64%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 17.73%. Jim Chanos would check for issues.
495.53%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.92%. Joel Greenblatt would investigate advantages.
453.43%
Margin change of 453.43% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
479.36%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.43%. Joel Greenblatt would investigate advantages.
486.45%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.83%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.